Socio-economic impact of antiretroviral treatment in HIV patients. An economic review of cost savings after introduction of HAART

AIDS Reviews

Volumn 11, Issue 2, 2009, Pages 79-90

  Gonzalo, Teresa ^a,c   García Goñi, Manuel ^b,c   Muñoz Fernández, María Ángeles ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c IE BUSINESS SCHOOL   (Spain)

Author keywords

Costs; Economic impact; Economy; HAART; Highly active antiretroviral treatment; HIV AIDS; QALY; Quality of life per year

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABSENTEEISM; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS PATIENT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC DEVELOPMENT; EPIDEMIC; HEALTH CARE COST; HIGH RISK BEHAVIOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; JOB PERFORMANCE; QUALITY OF LIFE; REVIEW; SEXUAL BEHAVIOR; SOCIOECONOMICS; SPAIN; TREATMENT RESPONSE; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; ADOLESCENT; ADULT; CHILD; DRUG EFFECT; ECONOMICS; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; INFANT; MALE; MIDDLE AGED; MORTALITY; NEWBORN; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; COST SAVINGS; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; QUALITY OF LIFE; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 68049105043     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. UNAIDS. Report on the global AIDS epidemic. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS, World Health Organization WHO; 2007.
2. Holguin A, Ramirez de Arellano E, Rivas P, Soriano V. Efficacy of anti-retroviral therapy in individuals infected with HIV-1 non-B subtypes. AIDS Rev. 2006;8:98-107.
3. Epidemiology SNC. HIV/AIDS Epidemiological Surveillance in Spain, National Register of AIDS cases: Secretariat of the National Plan on AIDS, Spanish National Center of Epidemiology; 2007.
4. Hughes A, Barber T, Nelson M. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. J Infect. 2008;57:1-10.
5. Markowitz M, Morales-Ramirez J, Nguyen B, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006;43:509-15.
6. Qian K, Morris-Natschke S, Lee K. HIV entry inhibitors and their potential in HIV therapy. Med Res Rev. 2009;29:369-93.
7. Manfredi R, Sabbatani S. A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20). Curr Med Chem. 2006;13:2369-84.
8. Daar E. Emerging resistance profiles of newly approved antiretroviral drugs. Top HIV Med. 2008;16:110-16.
9. Badia X, Lizan L, Magaz S, Sanz A, Green J, Serrano D. Cost-effectiveness analysis of enfuvirtide (ENF) added to an optimized therapy compared with an optimized therapy in patients with HIV/AIDS. HIV Clin Trials. 2007;8:235-45.
10. Rodes B, Garcia F, Gutierrez C, et al. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. J Med Virol. 2005;77:23-8.
11. UNAIDS. A Guide to Monitoring and Evaluation: National AIDS Programmes, UNAIDS; 2007.
12. WHO. Sexually transmitted infections HIV/AIDS programme. WHO/Europe survey on HIV/AIDS and antiretroviral therapy Copenhagen: World Health Organization (WHO), Regional Office for Europe; 2006.
13. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced HIV infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-60.
14. Perelson A, Neumann A, Markowitz M, Leonard J, Ho D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582-6.
15. Services USDHH. A Guide to Primary Care for People with HIV/AIDS: United States Department of Health and Human Services; 2004.
16. Attacking AIDS with a therapy. US Food and Drug Administration, 1999. (Accessed at http://www.fda.gov/FDAC/features/1999/ 499_aids.html.)
17. Mompo C, Abbas I, Santin M, et al. [Health care resources utilization in HIV-infected patients: creation of a data base and cost results]. Gac Sanit. 2000;14:39-47.
18. Theobald S, Raven J, Tolhurst R, Makwiza I, Taegtmeyer M. Public health approach to HIV treatment in resource-poor settings. Lancet 2006; 368:1064.
19. Guerra Romero L, Stanley K, Parras Vazquez F. [The natural history of the antiretrovirals: the continuum of their evaluation]. Med Clin (Barc). 1999;112(Suppl 1):59-66.
20. Dore G, Cooper D. HAART's first decade: success brings further challenges. Lancet. 2006;368:427-8.
21. Hogg R, Weber A, Craib K, et al. One world, one hope: the cost of providing antiretroviral therapy to all nations. AIDS. 1998;12:2203-9.
22. Binswanger HP. Public health. HIV/AIDS treatment for millions. Science. 2001;292:221-3.
23. Velasco M, Losa J, Espinosa A, et al. Economic evaluation of assistance to HIV patients in a Spanish hospital. Eur J Intern Med. 2007;18:400-4.
24. Beck E, Kennelly J, McKevitt C, et al. Changing use of hospital services and costs at a London AIDS referral centre, 1983-1989. AIDS. 1994;8:367-77.
25. Youle M, Trueman P, Simpson K. Health economics in HIV disease. A review of the European literature. Pharmacoeconomics. 1999;15(Suppl 1): 1-12.
26. Gebo K, Chaisson R, Folkemer J, Bartlett J, Moore R. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS. 1999;13:963-9.
27. Llibre-Codina JM, Casado-Gomez MA, Sanchez-de la Rosa R, et al. [Cost of nucleoside analogue reverse transcriptase inhibitor-related toxicity in HIV-1-infected patients]. Enferm Infecc Microbiol Clin. 2007;25:98-107.
28. Pinto J, Lopez Lavid C, Badia X, Coma A, Benavides A. [Cost effectiveness analysis of highly active antiretroviral therapy in HIV asymptomatic patients]. Med Clin (Barc). 2000;114(Suppl 3):62-7.
29. Ginestal J. The regional cost of AIDS in Spain. In: al. Se, ed. Economic aspects of AIDS and HIV infection. Berlin: Springer-Verlag; 1990:195-203.
30. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS. 1997;11:F101-5.
31. Bozzette S, Joyce G, McCaffrey D, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001;344:817-23.
32. Wallace M, Tasker S, Shinohara Y, Hill H, Chapman G, Miller L. The changing economics of HIV care. AIDS Patient Care STDS. 2001;15: 25-9.
33. Simpson K, Jones W, Rajagopalan R, Dietz B. Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in anti- retroviral-experienced patients in the UK, France, Italy and Spain. Clin Drug Investig. 2007;27:807-17.
34. Cleary S, McIntyre D, Boulle A. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa-a primary data analysis. Cost Eff Resour Alloc. 2006;4:20.
35. Paltiel A, Walensky R, Schackman B, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med. 2006;145:797-806.
36. Messeri P, Lee G, Abramson D, Aidala A, Chiasson M, Jessop D. Anti-retroviral therapy and declining AIDS mortality in New York City. Med Care. 2003;41:512-21.
37. Indexmundi GDP per capita. (Accessed at www.indexmundi.com.)
38. Beck E, Miners A, Tolley K. The cost of HIV treatment and care. A global review. Pharmacoeconomics. 2001;19:13-39.
39. Sendi P, Bucher H, Harr T, et al. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. AIDS. 1999;13:1115-22.
40. Borrell C, Rodriguez-Sanz M, Pasarin M, et al. AIDS mortality before and after the introduction of highly active antiretroviral therapy: does it vary with socioeconomic group in a country with a National Health System? Eur J Public Health. 2006;16:601-8.